Testing Neratinib or Neratinib with Palbociclib for HER2+ Tumors
Phase 2
70
about 2.8 years
18+
184 sites in AK, AL, CA +28
What this study is about
This trial is testing whether neratinib alone, or neratinib combined with palbociclib, is effective in treating HER2-positive solid tumors. These medications are kinase inhibitors that block a protein called HER2 to slow cancer growth.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Neratinib Maleate
- 2.Take Palbociclib
- 3.Undergo Biopsy Procedure
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Antineoplastic Agent [TC] (Kinase Inhibitors), palbociclib
oral (Oral Tablet), oral (Oral Capsule)
Primary: Progression free survival
Secondary: Overall survival
biopsy, diagnostic, imaging
Oncology